KR101603351B1 - 췌장암의 치료를 위해 젬시타빈과 조합된 중쇄 길이 지방산, 이의 염 및 트리글리세라이드 - Google Patents

췌장암의 치료를 위해 젬시타빈과 조합된 중쇄 길이 지방산, 이의 염 및 트리글리세라이드 Download PDF

Info

Publication number
KR101603351B1
KR101603351B1 KR1020107015015A KR20107015015A KR101603351B1 KR 101603351 B1 KR101603351 B1 KR 101603351B1 KR 1020107015015 A KR1020107015015 A KR 1020107015015A KR 20107015015 A KR20107015015 A KR 20107015015A KR 101603351 B1 KR101603351 B1 KR 101603351B1
Authority
KR
South Korea
Prior art keywords
gemcitabine
cancer
compound
treatment
pancreatic cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107015015A
Other languages
English (en)
Korean (ko)
Other versions
KR20100101134A (ko
Inventor
리네 게그논
릴리안네 절츠
크리스토퍼 페니
Original Assignee
프로메틱 바이오사이언시즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로메틱 바이오사이언시즈 인코포레이티드 filed Critical 프로메틱 바이오사이언시즈 인코포레이티드
Publication of KR20100101134A publication Critical patent/KR20100101134A/ko
Application granted granted Critical
Publication of KR101603351B1 publication Critical patent/KR101603351B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020107015015A 2007-12-19 2008-12-18 췌장암의 치료를 위해 젬시타빈과 조합된 중쇄 길이 지방산, 이의 염 및 트리글리세라이드 Expired - Fee Related KR101603351B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US812907P 2007-12-19 2007-12-19
US61/008,129 2007-12-19

Publications (2)

Publication Number Publication Date
KR20100101134A KR20100101134A (ko) 2010-09-16
KR101603351B1 true KR101603351B1 (ko) 2016-03-14

Family

ID=40795145

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107015015A Expired - Fee Related KR101603351B1 (ko) 2007-12-19 2008-12-18 췌장암의 치료를 위해 젬시타빈과 조합된 중쇄 길이 지방산, 이의 염 및 트리글리세라이드

Country Status (15)

Country Link
US (1) US8946190B2 (enExample)
EP (1) EP2231166B1 (enExample)
JP (1) JP5473937B2 (enExample)
KR (1) KR101603351B1 (enExample)
CN (1) CN101903028B (enExample)
AU (1) AU2008338204B2 (enExample)
BR (1) BRPI0821395A2 (enExample)
CA (1) CA2708679C (enExample)
DK (1) DK2231166T3 (enExample)
ES (1) ES2414617T3 (enExample)
MX (1) MX2010006867A (enExample)
NZ (1) NZ586249A (enExample)
PT (1) PT2231166E (enExample)
TW (1) TWI448290B (enExample)
WO (1) WO2009076761A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2427416E (pt) 2009-05-04 2016-06-15 Prometic Pharma Smt Ltd Compostos aromáticos substituídos e seus usos farmacêuticos
SG10201807622WA (en) * 2010-10-27 2018-10-30 Prometic Pharma Smt Ltd Compounds and compositions for the treatment of cancer
CN102617679B (zh) * 2012-03-13 2014-11-26 北京大学 一种共轭亚油酸与吉西他滨连接的前体药物制备方法及其应用
US9737538B2 (en) 2013-02-12 2017-08-22 Bend Research, Inc. Solid dispersions of low-water solubility actives
EP2956121B1 (en) 2013-02-12 2018-05-30 Bend Research, Inc. Solid dispersions of low-water solubility actives
EP3578170A1 (en) * 2013-02-28 2019-12-11 Basf As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
WO2015116782A1 (en) 2014-01-29 2015-08-06 Board Of Regents, The University Of Texas System Nucleobase analogue derivatives and their applications
MA53188A1 (fr) 2018-10-11 2021-12-31 Basf As Composés aromatiques et leurs utilisations pharmaceutiques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083120A2 (en) * 2001-04-18 2002-10-24 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
WO2004069237A1 (en) 2003-02-07 2004-08-19 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU641356B2 (en) * 1989-03-13 1993-09-23 Cellegy Pharmaceuticals, Inc. Treatment of skin diseases and tumors
US6982091B2 (en) * 2001-08-29 2006-01-03 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
US20060012880A1 (en) * 2002-05-02 2006-01-19 Law Benjamin P Optical device with refractive and diffractive properties
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083120A2 (en) * 2001-04-18 2002-10-24 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
WO2004069237A1 (en) 2003-02-07 2004-08-19 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Annals of Surgical Oncology. 2007. Vol.14, No.12, pp.3620-3628.(Epub. 2007.09.26.)*

Also Published As

Publication number Publication date
AU2008338204B2 (en) 2015-03-05
PT2231166E (pt) 2013-06-17
ES2414617T3 (es) 2013-07-22
TWI448290B (zh) 2014-08-11
DK2231166T3 (da) 2013-06-24
CA2708679A1 (en) 2009-06-25
EP2231166A4 (en) 2012-02-22
CA2708679C (en) 2016-11-15
CN101903028A (zh) 2010-12-01
WO2009076761A1 (en) 2009-06-25
TW200934494A (en) 2009-08-16
US8946190B2 (en) 2015-02-03
CN101903028B (zh) 2013-06-05
MX2010006867A (es) 2010-08-31
US20100273731A1 (en) 2010-10-28
JP2011506492A (ja) 2011-03-03
JP5473937B2 (ja) 2014-04-16
BRPI0821395A2 (pt) 2015-06-16
EP2231166B1 (en) 2013-03-20
KR20100101134A (ko) 2010-09-16
AU2008338204A1 (en) 2009-06-25
NZ586249A (en) 2012-05-25
HK1151244A1 (en) 2012-01-27
EP2231166A1 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
KR101603351B1 (ko) 췌장암의 치료를 위해 젬시타빈과 조합된 중쇄 길이 지방산, 이의 염 및 트리글리세라이드
KR20140079831A (ko) 췌장암 및／또는 담도암 치료약
CA2286557A1 (en) Phorbol esters as anti-neoplastic agents
CN112566628A (zh) 预防和治疗癌症的药物组合物，包括棉酚、苯乙双胍和抗癌剂
WO2019085827A1 (zh) 一种去甲氯氮平的新用途
CN113786491A (zh) 一种含汉防己甲素、二氢槲皮素或槲皮素的抗肿瘤联用制剂
HK1151244B (en) Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
CN109045052B (zh) 用于治疗结肠癌的药物配方与应用
CN111617073A (zh) 一种用于治疗肺癌的药物组合物及其应用
CN111558045A (zh) 一种治疗肺癌的药物组合物
US20070269531A1 (en) Non-Steroid Anti-Inflammatory Agents with Vitamins, Minerals, and Dietary Supplements for the Prevention and Treatment of Primary, Secondary and Tertiary Cancer
US20240390352A1 (en) Pharmaceutical composition for preventing or treating cancer comprising carnitine acylcarnitine carrier inhibitor and antitumor agent
EP4282408A1 (en) Method for pretreating relapsing cancer
CN109846876B (zh) 木脂素类化合物在抗肿瘤中的应用及其药物制备
CN110876803B (zh) 一种包含乳蛋白和油酸的药物组合物
Tsuda et al. Antineoplaston AS2-1 for maintenance therapy in liver cancer
KR20230043064A (ko) 카르니틴 아실카르니틴 운반자 억제제 및 항암제를 포함하는 암 예방 또는 치료용 약학적 조성물
US20040116354A1 (en) Supplementary immunotherapeutics to be used after lung cancer removal
CN114515288A (zh) 异喹啉类化合物在制备治疗食道癌药物中的应用
CN106420789A (zh) 复发耐药消化道肿瘤地西他滨综合治疗方案
CN115089570A (zh) 一种治疗肿瘤的药物组合物及其制剂和应用
CN110755430A (zh) 一种vegfr抑制剂与降压药组合物及其应用
WO2008064596A1 (fr) Composition pharmaceutique comprenant la protéine p43 pour le traitement de l'adénocarcinome gastrique
HK40049617A (en) Pharmaceutical composition for preventing or treating cancer, comprising gossypol, phenformin, and anticancer agent
CN110433172A (zh) 一种具有治疗非小细胞肺癌功效的药物及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230309

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230309